Hansoh Pharmaceutical Group's (HKG:3692) HS-20093 for injection obtained China's National Medical Products Administration's (NMPA) approval to be added as a breakthrough-therapy-designated drug for the treatment of patients with osteosarcoma, a type of bone cancer, a Tuesday bourse filing said.

The Chinese regulator approved the drug for the treatment of patients who have progressed on at least two prior lines of therapy.

HS-20093, also known as GSK5764227, is a B7-H3-targeted antibody-drug conjugate that is being developed in multiple clinical studies of small-cell lung cancer, head and neck cancers, and other solid tumors.

The injection has also been granted breakthrough therapy designation by NMPA previously for lung cancer and from the US Food and Drug Administration for the treatment of relapsed or refractory extensive-stage small-cell lung cancer, ES-SCLC.